2812. Clinical Impact of the Ceftolozane-Tazobactam Shortage on Difficult-To-Treat Resistant Pseudomonas aeruginosa Infections at an Academic Medical Center

BACKGROUND: Difficult-to-treat resistant Pseudomonas aeruginosa (DTR PA) infections are a serious threat, requiring treatment with ceftolozane-tazobactam (C/T), ceftazidime-avibactam, or imipenem-cilastatin-relebactam due to extensive resistance. C/T was unavailable January to December 2021 so alter...

Descripción completa

Detalles Bibliográficos
Autores principales: Vance, Mary K, Cimino, Christo, Ereshefsky, Benjamin, Humphries, Romney, Nelson, George E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678476/
http://dx.doi.org/10.1093/ofid/ofad500.2423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678476/
http://dx.doi.org/10.1093/ofid/ofad500.2423

Ejemplares similares